| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
BioVie Inc.$2.27
+0.03 (+1.34%)
D 34Pipeline Score Fair Value Biotech · Clinical
Market Cap
11.46 M
EPS
-4.27
P/E Ratio
-
Value Trade
242.61 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
3.18 M
Total Assets
17.51 M
Total Liabilities
1.91 M
Equity
15.61 M
D/E Ratio
12,345
12.59 %
Week
-4.4 %
1 Month
16.03 %
3 Month
20.63 %
6 Month
-99.89 %
5 Year
-99.98 %
All Time
Cash Data
Cash Position
13.10 M
Monthly Burn
1.79 M
Runway
5.3 mo
Burn Trend
StableSEC Filing
May 11, 2026
Overview
Volume
172.60 K
52 Week Range
1.06 - 12.10
% held by Insiders
4.75 %
% held by Institutions
13.8 %
Enterprise Value
-1.34 M
Total Shares
7.54 M
Short %
6.31 %
Float Shares
7.11 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for BioVie Inc.
293Total events
2Upcoming
62Tier-1 (high impact)
2018 – 2026Coverage
Upcoming catalysts 2
Event history 291
Q3 2026
◆Topline ReadoutbezisterimClinical Data
Topline results for SUNRISE-PD trial
Parkinson's diseasesource ↗
May 26, 2026
May 18, 2026
▲Last Patient Last VisitbezisterimTrial
Last patient evaluation visit completed for SUNRISE-PD Phase 2 trial
early-stage Parkinson's diseasesource ↗
May 7, 2026
◆Oral PresentationbezisterimPresentation
Virtual KOL event to discuss Phase 2 study of bezisterim for Parkinson's disease
Parkinson's diseasesource ↗
Apr 20, 2026
◆Poster PresentationbezisterimPresentation
Abstract accepted for poster presentation at AAN 2026 on SUNRISE-PD baseline demographics
Parkinson's Diseasesource ↗
Q2 2026
◆Topline ReadoutbezisterimClinical Data
Topline data from Phase 2 SUNRISE-PD trial of bezisterim for Parkinson's disease
Parkinson's diseasesource ↗
Mar 17, 2026
◆Poster PresentationbezisterimPresentation
Abstract accepted for poster presentation at AD/PD 2026
Parkinson's Diseasesource ↗
Mar 12, 2026
▲Enrollment CompletebezisterimTrial
SUNRISE-PD completed enrollment of 60 patients
Parkinson's Diseasesource ↗
Feb 18, 2026
◆Poster PresentationbezisterimPresentation
Poster presentation on bezisterim-associated anti-inflammatory epigenetic modulation in Alzheimer's Disease at ACP 2026
Alzheimer's Diseasesource ↗
Feb 12, 2026
Drug Pipeline Intelligence
D34
Pipeline Score $11M
Pipeline ValueFair Value
Valuation Signal2
Drugs Scored1.0x
rNPV / MCap Top 46%
Micro Cap (rank 493 of 912)
Percentile RankBioVie Inc. faces pipeline headwinds (34/100), with $1.2B risk-adjusted pipeline value, led by NE3107 in Alzheimer Disease (Phase 3), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NE3107 Small molecule | Alzheimer Disease | Phase 3 | NCT05227820 | 48% | $837M | COMPLETED | 462 | - | - | Aug 20, 2022 | - | Jul 9, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
bezisterim | Parkinson's disease | Phase 2 | 2026-04-27 | patients with moderate- to severe stage Parkinson’s disease taking bezisterim with levodopa had better motor control and reported fewer morning symptoms compared to those taking levodopa alone. Read More | BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026 Read More | |
bezisterim | Parkinson's disease | Phase 2 | 2026-04-27 | patients with moderate- to severe stage Parkinson’s disease taking bezisterim with levodopa had better motor control and reported fewer morning symptoms compared to those taking levodopa alone. Read More | BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026 Read More | |
bezisterim | Parkinson's disease | Phase 2 | 2026-04-27 | patients with moderate- to severe stage Parkinson’s disease taking bezisterim with levodopa had better motor control and reported fewer morning symptoms compared to those taking levodopa alone. Read More | BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BIVI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BIVI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BIVIJoin BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2
BioVie Inc. is hosting a live investor webinar on June 2, 2026, featuring CEO Cuong Do. The presentation will cover bezisterim, an investigational drug for neuroinflammation, and BIV201, a late-stage candidate for liver disease. The event will include a Q&A session, highlighting BioVie's progress and market opportunities.
Read more →BIVI▼ -5.3%on this newsshared move
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
BioVie Inc. has announced the full enrollment of its ADDRESS-LC Phase 2 trial, which evaluates bezisterim for treating neurological symptoms associated with Long COVID. The study is fully funded by a U.S. Department of War grant and aims to assess the drug's efficacy in alleviating cognitive impairment and fatigue. Topline data is expected to be released in late summer 2026.
Read more →BIVIBioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease
BioVie Inc. has completed the last patient evaluation visit for its Phase 2 SUNRISE-PD trial, which assesses the drug bezisterim in early-stage Parkinson's disease. The trial aimed to evaluate motor and non-motor endpoints and will now enter the closeout phase, with topline results anticipated in Q3 2026. The study utilized a hybrid decentralized design to enhance patient participation.
Read more →BIVI▲ +6%on this news
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026
BioVie Inc. will host a virtual KOL event on May 7, 2026, to discuss the Phase 2 study of bezisterim for Parkinson's disease. The event will feature Dr. Suzanne de la Monte, who will elaborate on bezisterim's mechanism of action. The drug has shown promise in improving motor control in patients and is being evaluated for its potential benefits in neurodegenerative diseases.
Read more →BIVI▲ +5.8%on this news
BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting
BioVie Inc. announced that an abstract from its SUNRISE-PD study on bezisterim has been accepted for presentation at the 2026 American Academy of Neurology Annual Meeting. The abstract will summarize initial data on patients with Parkinson's Disease and will be presented during a session focused on emerging therapeutics. Topline results from the study are anticipated in mid-2026.
Read more →BIVIBioVie Announces Abstract Accepted for Presentation at AD/PD 2026
BioVie Inc. announced that its abstract on bezisterim (NE3107) for Parkinson's disease has been accepted for presentation at the AD/PD 2026 conference in Copenhagen. The abstract summarizes initial data from the SUNRISE-PD study, which evaluates bezisterim's efficacy in early Parkinson's patients. Topline results are anticipated in mid-2026, highlighting the company's ongoing research in neurodegenerative diseases.
Read more →BIVIJoin Biovie’s Exclusive Live Investor Webinar and Q&A Session on March 4
BioVie Inc. is inviting investors to a webinar on March 4, 2026, featuring CEO Cuong Do. The session will cover the investigational drug bezisterim, which targets neuroinflammation and insulin resistance, and the orphan drug BIV201 for liver disease. The company is advancing multiple clinical programs with potential late-stage developments.
Read more →BIVIBioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting
BioVie Inc. announced the acceptance of two abstracts for its lead candidate, bezisterim, at the 2026 American College of Psychiatrists annual meeting. The abstracts focus on bezisterim's effects on Alzheimer's disease and Long COVID. The company has seen promising results in previous trials for Parkinson's disease and continues to explore bezisterim's therapeutic potential.
Read more →BIVIBioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson’s Disease
BioVie Inc. has successfully completed the enrollment of 60 participants in its Phase 2 SUNRISE-PD clinical trial, which is assessing the efficacy of bezisterim for early Parkinson's disease. This study focuses on individuals who have not previously received treatment with carbidopa/levodopa, utilizing a hybrid trial design to improve patient access. With topline results expected in the first half of 2026, the trial aims to explore how bezisterim may influence the progression of Parkinson's symptoms. The company's efforts were supported by prominent advocacy organizations in the Parkinson's community.
Read more →BIVIBIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating BioVie Inc. on behalf of long-term stockholders due to a class action complaint filed on January 19, 2024. The investigation focuses on allegations that BioVie breached fiduciary duties amidst significant issues discovered in its Phase 3 clinical trial for NE3107, intended for Alzheimer's treatment. The trial faced serious complications with data integrity and participant exclusions, leading to a 60% drop in share price following the trial's announcement. Stakeholders are encouraged to contact the law firm to explore their legal options.
Read more →BIVIBioVie to Host Live Investor Webinar and Q&A on Oct. 8
BioVie Inc. will host a live investor webinar on October 8, 2025, to discuss its innovative drug therapies for neurological diseases. CEO Cuong Do will present findings on bezisterim, which shows promise in treating Alzheimer’s and Parkinson’s diseases. The session will also cover BIV201, an orphan drug candidate for liver cirrhosis. A Q&A will follow the presentation.
Read more →BIVIBioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes
BioVie Inc. announced the presentation of its ADDRESS-LC Phase 2 trial design at the Keystone Symposia. The trial evaluates bezisterim's efficacy in treating neurological symptoms of Long COVID, a condition affecting millions. The study is fully funded by the U.S. Department of Defense and aims to address significant unmet medical needs.
Read more →BIVI▼ -6.7%on this newsshared move
BioVie Inc. Announces Closing of $12 Million Public Offering
BioVie Inc. has successfully closed a $12 million public offering, selling 6 million units at $2.00 each. The offering included warrants that are now listed on the Nasdaq Capital Market. The funds raised will be utilized for working capital and general corporate purposes. The company is focused on developing therapies for chronic conditions, including liver disease and neurodegenerative disorders.
Read more →BIVI▼ -42.6%on this newsshared move
BioVie Inc. Announces Pricing of $12 Million Public Offering
BioVie Inc. has announced the pricing of its $12 million public offering, which includes 6,000,000 units priced at $2.00 each. The offering is set to close on August 11, 2025, and proceeds will be used for working capital and general corporate purposes. The warrants included in the offering are expected to trade on the Nasdaq Capital Market.
Read more →BIVI▼ -8.4%on this news
BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology
BioVie Inc. presented findings at the 2nd World Conference on Aging and Gerontology, indicating that bezisterim may decelerate biological aging in Alzheimer's patients compared to placebo. The drug targets inflammation and has shown promise in improving healthspan. Ongoing studies aim to further explore its efficacy in Alzheimer's and other neurodegenerative diseases.
Read more →BIVI▲ +12%on this newsshared move
BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors
BioVie Inc. has appointed Dr. Amy Chappell and Mr. Kameel Farag to its Board of Directors. Both bring extensive experience in drug development and biotech operations, which will support BioVie as it advances its clinical programs for neurological disorders. The company is currently progressing with its Phase 2 trials for bezisterim and other initiatives.
Read more →BIVIBioVie Announces Data Highlighting Bezisterim’s Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and Rejuvenation Conference
BioVie Inc. presented data on bezisterim's potential to slow biological aging and neurodegeneration at the 7th World Aging and Rejuvenation Conference. The drug, which modulates inflammation, may offer a new strategy for treating Alzheimer's and other neurodegenerative diseases. Ongoing studies are expected to provide further insights into its efficacy.
Read more →BIVIBioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)
BioVie Inc. presented a poster on its SUNRISE-PD Phase 2 trial at the ATMRD Congress, emphasizing its patient-centric design aimed at improving access for individuals with early-stage Parkinson's disease. The trial evaluates bezisterim (NE3107) and allows participants to engage through home visits or clinics. This innovative approach seeks to broaden participation in PD research and enhance treatment outcomes.
Read more →BIVIBioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress
BioVie Inc. announced the presentation of its Phase 2 SUNRISE-PD trial at the Advanced Therapeutics in Movement & Related Disorders Congress. The trial evaluates bezisterim (NE3107) for early Parkinson's disease, utilizing a hybrid decentralized approach. Results are expected in late 2025 or early 2026, following a previous successful Phase 2 study.
Read more →BIVIBioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
BioVie Inc. has enrolled the first patient in its Phase 2 ADDRESS-LC clinical trial, evaluating bezisterim for treating neurological symptoms associated with long COVID. The trial aims to assess the efficacy and safety of bezisterim, which targets neuroinflammation. Topline data is expected in the first half of 2026, addressing a significant unmet medical need.
Read more →BIVIBioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025
BioVie Inc. announced plans to host a virtual key opinion leader event on May 28, 2025, to discuss the Phase 2 trial of bezisterim for treating Parkinson's disease. Esteemed experts from Brown University and the Medical University of South Carolina will present insights into the current treatment landscape and the trial's objectives. Bezisterim, an oral medication, aims to counteract inflammation and insulin resistance, which are significant factors in Parkinson's disease. The trial is currently enrolling patients who have recently been diagnosed and have not yet started treatment, with topline data expected in late 2025 or early 2026.
Read more →BIVI▼ -6.9%on this news
BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson’s Disease and Related Disorders (IAPRD 2025)
BioVie Inc. will present the rationale and design of its Phase 2 SUNRISE-PD clinical trial for bezisterim (NE3107) at the 30th World Congress on Parkinson's Disease and Related Disorders. The trial aims to evaluate the safety and effectiveness of bezisterim in patients with early Parkinson's disease. Participants may join the trial from home or in clinical settings, allowing for flexible patient engagement. Preliminary data from previous studies suggest possible benefits, although final outcomes are pending further evaluations.
Read more →BIVI▼ -5.8%on this newsshared move
BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth
BioVie has announced the formation of a new Corporate Advisory Board comprised of seven industry leaders, including experts from Cedars-Sinai and Neuralink. The board aims to support BioVie’s development of innovative therapies for neuroinflammatory conditions such as Alzheimer’s and Parkinson’s diseases. They will leverage their expertise to drive clinical development, inform business strategy, and engage stakeholders. BioVie’s investigational drug candidate, bezisterim (NE3107), is highlighted as a potential breakthrough in treating these conditions, supported by ongoing clinical trials.
Read more →BIVIBioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson’s Disease with First Patient Enrolled
BioVie Inc. has launched the SUNRISE-PD clinical trial to evaluate bezisterim in patients with early Parkinson's disease who have not previously received treatment. The trial aims to explore bezisterim's effects on both motor and non-motor symptoms through a decentralized approach that allows remote participation. This is a notable addition to Parkinson's treatment research, with topline data expected in late 2025 or early 2026. The trial has garnered support from prominent organizations dedicated to Parkinson's research and patient advocacy.
Read more →BIVIBioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025
BioVie Inc. announced a virtual investor event featuring Dr. Lindsay McAlpine to discuss the current treatment landscape for long COVID. The meeting will address the unmet need for therapies and provide insights into the ADDRESS-LC trial evaluating bezisterim, a new drug candidate targeting neuroinflammation in long COVID patients. The event is scheduled for April 10, 2025. With no effective treatments currently available, the trial represents a significant step toward addressing the lingering effects of COVID-19.
Read more →BIVIBioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
BioVie Inc. has announced that an abstract detailing the design of its planned Phase 2 trial for bezisterim, aimed at treating Long COVID, has been accepted for presentation at the Demystifying Long COVID International Conference. This double-blind, randomized trial, funded by a $13 million grant from the U.S. Department of Defense, will evaluate the safety, tolerability, and potential efficacy of bezisterim in approximately 200 patients experiencing neurocognitive symptoms. The conference will take place on November 21st and 22nd, 2024, in Barcelona, Spain.
Read more →BIVI▼ -9.4%on this news
BioVie’s Upcoming Parkinson’s Disease Clinical Trial is Fully Funded
BioVie Inc. has announced that it has completely funded its upcoming clinical trial, the PD-202 study, for Bezisterim aimed at treating early Parkinson's disease. The funding comes from a successful capital raise of over $15 million through secondary offerings. This Phase 2 trial is set to begin in early 2025, with topline results anticipated by late 2025. BioVie is also planning to initiate several other clinical trials for conditions such as Long COVID and Alzheimer's Disease in the same timeframe.
Read more →BIVI▼ -10.8%on this news
BioVie Inc. Announces Closing of Registered Direct Offering Carson City, Nevada
BioVie Inc. has announced the closure of its registered direct offering of 1,146,000 shares, priced at $2.83 per share, raising a total of $3,243,180. The company intends to utilize the net proceeds primarily for working capital and corporate purposes. This funding is crucial as BioVie develops therapies for chronic conditions, including neurological disorders and liver disease. The offering followed compliance with SEC regulations, ensuring transparency in the company’s fund-raising efforts.
Read more →BIVIBioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Carson City, Nevada
BioVie Inc. has announced the pricing of a registered direct offering of 1,146,000 shares of its common stock at $2.83 per share, aiming to raise around $3.2 million. The offering is set to close on or about October 29, 2024, pending customary closing conditions. The funds generated will primarily support working capital and general corporate purposes. This move highlights BioVie’s commitment to advancing their clinical-stage therapies targeting chronic conditions such as liver disease and neurodegenerative disorders.
Read more →BIVI▲ +5.4%on this newsshared move
BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement Carson City, Nevada
BioVie Inc. has announced the closing of a registered direct offering of 2,667,000 shares at a price of $2.25 per share, coupled with a concurrent private placement of unregistered warrants. The company expects to utilize the $6,000,750 raised primarily for working capital and corporate purposes. BioVie focuses on developing innovative therapies for chronic liver and neurodegenerative diseases, with active candidates moving through clinical testing. However, the lack of registration on the warrants and uncertainties about future capital raises present certain risks.
Read more →BIVI▼ -23.5%on this newsshared move
BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules Carson City, Nevada
BioVie Inc. has announced the pricing of a registered direct offering for 2,667,000 shares at $2.25 per share, generating total gross proceeds of $6,000,750. This fundraise will primarily support working capital and corporate purposes. Alongside this offering, the company is also issuing unregistered warrants exercisable at a later date. The expected closing date for these transactions is October 24, 2024, subject to customary conditions. BioVie is focused on developing therapies for neurological conditions and advanced liver disease.
Read more →BIVI▲ +27.8%on this newsshared move
BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement
BioVie Inc. has closed a registered direct offering of 4,443,000 shares priced at $1.50 each, raising approximately $6.66 million in gross proceeds. Additionally, the company conducted a concurrent private placement involving unregistered warrants for the same number of shares at an exercise price of $1.37. The funds will be primarily used for working capital and general corporate purposes. The offerings were facilitated by ThinkEquity and included certain regulatory disclosures as mandated by the SEC.
Read more →BIVIBioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin
BioVie Inc. has received a Notice of Allowance from the Japan Patent Office for its novel liquid formulation of terlipressin, which is expected to boost its intellectual property protection. This formulation offers significant advantages, including room-temperature stability for 24 months and a pre-filled syringe format to enhance patient convenience. BioVie has already secured patents in multiple countries, including the U.S., India, and Chile, with applications pending in several other markets. The new formulation aims to improve treatment options for patients suffering from ascites and hepatic failure.
Read more →BIVIBioVie Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of Terlipressin
BioVie Inc. has received a Notice of Allowance from the US Patent and Trademark Office for its patent application on a new liquid formulation of terlipressin. This formulation has demonstrated stability at room temperature for 24 months, which could significantly improve treatment for patients with cirrhosis and ascites in home-care environments. BioVie has also secured similar patent protections in India and Chile, with pending applications in nine more markets. The company anticipates this patent will bolster its intellectual property position and enhance the value of its BIV201 program.
Read more →BIVIBioVie Inc. Announces Closing of Public Offering
BioVie Inc. has successfully closed a public offering, raising about $3 million for its clinical-stage drug development. The offering consisted of shares and warrants, with the funds intended for working capital and corporate purposes. BioVie is focused on innovative therapies targeting neurodegenerative disorders and liver disease. They have reported positive data from various clinical studies, including improvements for patients with Alzheimer's and Parkinson's disease, as well as received FDA Fast Track designation for their liver disease candidate.
Read more →BIVIBioVie Inc. Announces Closing of Public Offering Carson City, Nevada
BioVie Inc. has closed a public offering of 1,360,800 shares of its common stock, along with pre-funded warrants and common warrants, raising about $3 million. The company plans to utilize the net proceeds for working capital and general corporate needs. Notably, BioVie focuses on developing therapies for chronic conditions including neurological and neurodegenerative disorders, and advanced liver disease. The public offering reflects BioVie's ongoing efforts to fund its promising drug candidates, particularly NE3107 and BIV201.
Read more →BIVI▼ -57.9%on this newsshared move
BioVie Inc. Announces Pricing of Public Offering
BioVie Inc. has announced the pricing of a public offering of 1,960,800 shares of its common stock and associated warrants, set at $1.53 per share. The offering is projected to generate approximately $3,000,000 before fees, which will be used for working capital and corporate purposes. The expected closing date for the offering is September 25, 2024, pending customary closing conditions. The company continues to develop therapies for serious chronic conditions, including Alzheimer’s and liver diseases.
Read more →BIVIBioVie Inc. Announces Proposed Public Offering
BioVie Inc. announced its intention to conduct a public offering of common stock and accompanying warrants, primarily for working capital. The offering will be managed by ThinkEquity and hinges on current market conditions without guarantees on completion. The company is advancing innovative treatments for neurological disorders and liver diseases, with recent positive clinical trial data for its drug candidates. However, the firm acknowledges that various risks could impact its ability to raise capital and execute ongoing clinical studies.
Read more →BIVIBioVie Inc. Announces Proposed Public Offering Carson City, Nevada
BioVie Inc. announced its intention to conduct a public offering of common stock and warrants to enhance working capital and corporate purposes. The offering, managed by ThinkEquity, is contingent upon market conditions and includes a shelf registration statement previously filed with the SEC. The company focuses on developing treatments for advanced liver disease and neurodegenerative disorders, with promising trial results for candidates like NE3107 and BIV201.
Read more →BIVIBioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID
BioVie Inc. has received final approval from the U.S. Army Medical Research and Development Command for its Phase 2 trial evaluating bezisterim as a treatment for long COVID. This approval allows the company to unlock $12.6 million in grant funding from the Department of Defense to commence the trial, planned for early 2025. The trial will assess the safety and efficacy of bezisterim in approximately 200 patients suffering from neurological symptoms related to long COVID. Bezisterim is also being explored for its potential in treating neurological disorders such as Alzheimer's and Parkinson's diseases.
Read more →BIVIBioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID
BioVie Inc. announced the FDA's authorization of its Investigational New Drug application for bezisterim, aimed at treating neurological symptoms related to long COVID. The company is set to begin a Phase 2, multicenter, placebo-controlled trial, evaluating bezisterim's safety and efficacy in approximately 200 patients. This milestone enables BioVie to access an additional grant of $12.6 million from the U.S. Department of Defense to support the trial. Bezisterim, which targets inflammation, is also under investigation for other neurodegenerative diseases like Alzheimer’s and Parkinson’s.
Read more →BIVIBioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting
BioVie Inc. presented promising clinical data at the 11th Aging Research and Drug Discovery Meeting, revealing that bezisterim may modulate inflammation and impact the biological aging process. Patients treated with bezisterim experienced a significant age deceleration advantage, showing benefits in various biological age clocks. The drug demonstrates the ability to regulate DNA methylation of proinflammatory genes, potentially aiding in the treatment of neurodegenerative diseases. This foundational research could pave the way for future therapeutic strategies targeting aging and inflammation-related disorders.
Read more →BIVIBioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery Meeting
BioVie Inc. has announced a poster presentation featuring bezisterim at the upcoming 11th Aging Research and Drug Discovery Meeting in Copenhagen. The presentation will outline clinical data focusing on bezisterim's effects on biological aging and various neurological assessments. Bezisterim is being evaluated for its potential to treat Alzheimer's disease and other neurological disorders, with prior studies showing encouraging results related to cognitive function. Details of the findings will be released post-presentation.
Read more →BIVI▲ +13.3%on this newsshared move
BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson’s Disease
BioVie Inc. has announced alignment with the FDA regarding its SUNRISE-PD clinical trial for bezisterim in Parkinson's disease. This Phase 2 trial will involve approximately 60 patients who are newly diagnosed and aims to evaluate the drug's impact on motor and non-motor symptoms. The company is currently preparing for the trial, which is set to begin patient screening in the fourth quarter of 2024. Previous trials have indicated that bezisterim may significantly improve motor control in moderate to severe cases of the disease.
Read more →BIVI▼ -21.4%on this newsshared move
BioVie Inc. Announces Reverse Stock Split
BioVie Inc. has announced the implementation of a reverse stock split for its Class A common stock at a 1-for-10 exchange ratio, effective immediately. This decision followed the approval from stockholders at a special meeting held on July 29, 2024. The reverse stock split is aimed at improving trading conditions on the Nasdaq Capital Market, where BioVie will continue to be listed under the symbol 'BIVI'. BioVie focuses on developing therapies for neurological diseases and liver conditions, with its drug candidate BIV201 currently pursuing FDA Fast Track status for chronic liver cirrhosis.
Read more →BIVI▼ -5.3%on this news· ran to -16% by day 3
BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at ATMRD 2024
BioVie Inc. has announced the protocol design for its SUNRISE-PD Phase 2 trial, which will evaluate bezisterim (NE3107) in approximately 60 early Parkinson's disease patients who are naive to carbidopa/levodopa. This multicenter, randomized, double-blind, placebo-controlled trial will assess the drug's impact on motor and non-motor symptoms over 20 weeks, following promising preliminary results from earlier trials. Data presented at the ATMRD Congress highlighted bezisterim's potential as an adjunctive therapy, suggesting significant symptom improvements compared to placebo.
Read more →BIVIBioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at 2024 ATMRD Congress
BioVie Inc. has announced its intention to present the protocol design for an upcoming Phase 2 trial of bezisterim in patients with early Parkinson's disease at the Advanced Therapeutics in Movement and Related Disorders Congress. The protocol includes a placebo-controlled study assessing bezisterim's effect on motor symptoms in patients not yet treated with carbidopa/levodopa. Additionally, another presentation will provide data on how bezisterim impacts both motor and non-motor symptoms when used alongside existing treatments. The outcomes and conclusions from these studies will be shared following the congress.
Read more →BIVIBioVie Announces Formation of Advisory Board for Bezisterim in Long COVID
BioVie Inc. has formed an Advisory Board to aid in developing a Phase 2b trial for bezisterim, targeting long COVID. The Board consists of prominent experts in long COVID and neuropsychiatric clinical development to provide strategic guidance. Funding from the U.S. Department of Defense supports initial planning, with potential for additional funding to proceed with the clinical trial. Bezisterim aims to address cognitive and fatigue symptoms associated with long COVID.
Read more →BIVIBioVie’s Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson’s Disease Patients
BioVie Inc. announced positive results from a Phase 2a trial of bezisterim for Parkinson's Disease, showing significant improvements in both motor and non-motor symptoms compared to placebo. Patients treated with bezisterim experienced better scores in various measures, including sleep/fatigue and urge to move legs. Correlation in symptom improvements suggests potential for bezisterim as an adjunct therapy to levodopa. The findings were presented at the XXIX World Congress on Parkinson's Disease and Related Disorders in Lisbon.
Read more →BIVIBioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID
BioVie Inc. has received a grant of up to $13.1 million from the U.S. Department of Defense to fund a clinical trial evaluating bezisterim (NE3107) for treating neurological symptoms of long COVID. The Phase 2b trial aims to assess the safety and effectiveness of bezisterim, an anti-inflammatory and insulin-sensitizer that can penetrate the blood-brain barrier, with trials expected to start in early 2025. Given the prevalence and debilitating nature of long COVID symptoms, which affect approximately 17 million adults in the U.S., the trial could offer significant advancements in treatment options. This initiative is part of the Department of Defense's Peer Reviewed Medical Research Program.
Read more →BIVIBioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker Endpoints
BioVie Inc. presented new data on bezisterim (formerly NE3107) at the Alzheimer's & Parkinson's Drug Development Summit, revealing its potential to modulate DNA methylation associated with age-related diseases. The drug showed advantages in biological age reduction in clinical trials for Alzheimer's disease, suggesting a unique mechanism that prevents hypermethylation linked to inflammation. As the first drug to demonstrate such effects in clinical settings, bezisterim offers insights into treating neurodegenerative conditions. However, further research is required to confirm its long-term efficacy and safety.
Read more →BIVIBioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation
BioVie Inc. announced an upcoming oral and poster presentation at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit, showcasing data on NE3107, now named bezisterim. This drug candidate has shown potential in influencing biological age markers related to dementia and inflammation. The presentation will be led by BioVie’s Senior VP, Christopher L. Reading, on April 24. Previous trials reported efficacy in patients with mild to moderate Alzheimer's disease and improvements for Parkinson's patients treated with bezisterim.
Read more →BIVI▼ -8.4%on this news· ran to -20% by day 3
BIOVIE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against BioVie Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against BioVie Inc. on behalf of investors who purchased the company’s securities between August 2021 and November 2023. The lawsuit follows significant issues in BioVie’s Phase 3 clinical trial for NE3107, including major patient exclusions due to alleged GCP violations. After this information became public, BioVie’s stock saw a dramatic decline of over 60%. The lawsuit claims that the company misled investors regarding the oversight and reliability of its clinical trial data.
Read more →BIVIBioVie (BIVI) Faces Securities Fraud Class Action After Uncovering Potential Scientific Misconduct In Failed Phase 3 Clinical Trial – Hagens Berman
BioVie Inc. is facing a securities fraud class action as it allegedly misled investors about the oversight of its Phase 3 clinical trial for NE3107, a potential Alzheimer's treatment. The lawsuit claims the company failed to adhere to Good Clinical Practices and concealed significant issues during the trial, which ultimately missed its primary endpoints. Investors reacted negatively to the news of potential scientific misconduct, leading to a dramatic drop in share price. An investigation is underway to determine if BioVie intentionally concealed critical information about trial compliance.
Read more →BIVIBioVie Sued By Block & Leviton LLP for Securities Law Violations
Block & Leviton LLP has filed a class action lawsuit against BioVie, Inc. for alleged securities fraud related to misleading statements made during the company's clinical trial of NE3107 for Alzheimer's Disease. The lawsuit, covering the period from August 5, 2021, to November 29, 2023, comes on the heels of BioVie's report of significant protocol deviations and Good Clinical Practice violations in their Phase 3 trial. Following this disclosure, BioVie's stock price plummeted by more than 60%. The legal action claims that BioVie executives failed to provide critical oversight and transparency in their operations, thus misleading investors.
Read more →BIVIBioVie Announces Pipeline Update and Near-Term Clinical Priorities Recently completed financing provides sufficient funds for near-term Parkinson's Disease priority Plans for Phase 2b trial of NE3107 as first-line monoth
BioVie Inc. has announced a robust pipeline update, focusing on significant clinical priorities for neurodegenerative diseases like Parkinson's and Alzheimer's. With a successful recent financing round, the company plans to commence a Phase 2b trial for NE3107, designed as a first-line treatment for newly diagnosed Parkinson's patients, anticipated to launch in late summer 2024. Additionally, the company is preparing for an upcoming Phase 3 trial for BIV201, following feedback from the FDA, despite facing delays due to funding challenges. Overall, the clinical data presented shows promise in terms of treatment efficacy for significant neurological conditions.
Read more →BIVI▼ -43.7%on this news· ran to -61% by day 3shared move
BioVie Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline.
BioVie Inc. is facing a lawsuit filed on behalf of investors who purchased the company's securities between August 5, 2021, and November 29, 2023. The Portnoy Law Firm is advising these investors about potential recovery of their losses related to allegedly misleading statements made by BioVie regarding its clinical trial operations and compliance standards, particularly in light of COVID-19's impact. The company has acknowledged issues of scientific misconduct and non-compliance, which led to a significant drop in stock price and investor confidence.
Read more →BIVI▲ +52.4%on this newsshared move
BioVie Inc. Announces Proposed Public Offering of Common Stock Carson City, Nevada
BioVie Inc. has announced its intention to conduct a public offering of common stock as part of its ongoing funding strategy. The offering is subject to market conditions and will include possible pre-funded warrants. Proceeds from the offering are expected to be used primarily for working capital and corporate purposes. The company is involved in developing therapies for neurological disorders and advanced liver disease, and has promising clinical trial results for its product candidates.
Read more →BIVI▲ +52.4%on this newsshared move
BioVie's NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson's Disease Patients and May Be Realigning Physiological Processes for Alzheimer's Patients in Data to be Presented at the I
BioVie Inc. announced promising results for its drug candidate NE3107 at the upcoming International Conference on Alzheimer's and Parkinson's Diseases. The Phase 2a trial showed significant improvements in both motor and non-motor symptoms in Parkinson's Disease patients, while data from a Phase 3 trial suggested potential benefits for Alzheimer's patients regarding neurocognitive decline. Although there were limitations regarding data integrity in the Alzheimer's trial, the findings indicate a potential therapeutic role for NE3107 in treating these neurodegenerative disorders.
Read more →BIVI▼ -5.6%on this news
BIOVIE SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In BioVie To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP is investigating potential claims against BioVie Inc. due to allegations of federal securities law violations. These include claims that BioVie failed to properly oversee its Phase 3 clinical trial for NE3107, which was impacted by the COVID-19 pandemic. As a result of significant deviations from clinical protocol, the trial did not achieve statistical significance and led to a major drop in the company's share price. A class action lawsuit has been filed, and investors affected by losses exceeding $25,000 are encouraged to take action before the March 19, 2024 deadline.
Read more →BIVI▲ +5%on this newsshared move
BioVie Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights – BIVI
BioVie Inc. is facing a class action securities fraud lawsuit filed by Levi & Korsinsky, which claims that the company mismanaged its Phase 3 clinical trial. The lawsuit alleges that BioVie failed to provide adequate oversight and that the COVID-19 pandemic further hindered its efforts. As a result of these issues, the Phase 3 trial data may be unreliable, and investor statements about the company's operations were misleading. Investors affected by these events are encouraged to contact Levi & Korsinsky before March 19, 2024, for potential legal recourse.
Read more →BIVI▲ +6.3%on this newsshared move
BioVie Inc. Class Action: The Gross Law Firm Reminds BioVie Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 – BIVI
BioVie Inc. is facing a class action lawsuit initiated by The Gross Law Firm, with a lead plaintiff deadline set for March 19, 2024. The allegations include claims of inadequate oversight during a critical Phase 3 clinical trial, exacerbated by the COVID-19 pandemic. It is asserted that due to reliance on contract research organizations, the trial data may be unreliable, leading to significant patient exclusions. The lawsuit further contends that the company's public statements were misleading regarding its operational compliance and business practices.
Read more →BIVIBIOVIE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In BioVie To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP is investigating potential claims against BioVie Inc. due to allegations of false and misleading statements regarding its Phase 3 clinical trial. The company faced major issues during the trial, including oversight failures and significant patient exclusions due to protocol violations. Following a disappointing announcement about the trial's performance, BioVie’s share price plummeted more than 60% on unusually high trading volume. Investors who incurred losses exceeding $25,000 between August 2021 and November 2023 are encouraged to contact the law firm before the March 19, 2024 lead plaintiff deadline.
Read more →BIVIBIOVIE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In BioVie To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP is investigating potential claims against BioVie Inc. as the March 19, 2024 deadline approaches for lead plaintiffs in a federal class action lawsuit. The complaint alleges that BioVie and its executives made misleading statements regarding their Phase 3 clinical trial oversight, particularly stressing the impact of COVID-19 and subsequent trial irregularities. On November 29, 2023, BioVie announced the trial's failure to meet primary endpoints after significant patient exclusions, resulting in a dramatic fall of over 60% in stock price.
Read more →BIVI▲ +5.8%on this newsshared move
BioVie to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
BioVie Inc. (NASDAQ: BIVI) has announced its participation in the Oppenheimer 34th Annual Healthcare Life Sciences Conference, scheduled virtually for February 13-14, 2024. The company is advancing therapies for neurological disorders and liver disease, particularly highlighting the NE3107 drug candidate which has shown efficacy in trials for Alzheimer's and Parkinson's diseases. BIV201, another of its drug candidates, has received FDA Fast Track designation for treating complications associated with chronic liver cirrhosis. Despite positive advancements, BioVie faces financial and regulatory challenges that could impact its future objectives.
Read more →BIVIBioVie Inc. (BIVI) Stockholder News: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in BioVie Inc. Class Action
BioVie Inc. is facing a class action lawsuit filed by shareholders for allegedly failing to disclose significant issues during its Phase 3 clinical trial for NE3107 in Alzheimer's Disease. The lawsuit claims that improper practices at clinical trial sites led to the exclusion of over 80% of enrolled patients, which in turn caused the trial to fail to achieve statistical significance. This news has severely impacted BioVie's stock price, which dropped by more than 60%. Shareholders have until March 19, 2024, to file as lead plaintiffs in the case.
Read more →BIVIBIOVIE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against BioVie Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against BioVie Inc., involving alleged misleading information provided to investors. The lawsuit is based on claims that throughout the class period, the company failed to disclose material adverse facts concerning its Phase 3 clinical trial for NE3107, particularly its oversight and compliance issues. Following the trial results release, which detailed significant protocol violations, BioVie saw its share price plummet over 60%. Investors now have until March 19, 2024, to apply as lead plaintiff in the lawsuit.
Read more →BIVIBioVie (BIVI) Plunges After Alzheimer’s Drug Fails Phase 3 Due to “Protocol Deviations” at Trial Sites – Hagens Berman
BioVie Inc. (BIVI) is facing scrutiny following protocol deviations in its Phase 3 clinical trial for NE3107, an Alzheimer's drug. The company revealed significant non-compliance with Good Clinical Practice (GCP) at several trial sites, leading to the exclusion of patients from the study. As a result, BioVie's stock dropped sharply, prompting an investigation into the company's disclosures and potential misconduct. Hagens Berman is urging affected investors to come forward and report their losses due to these developments.
Read more →BIVIBioVie Announces EfficacyData from Phase 3 Trial of NE3107 in Patientswith Mild to Moderate Alzheimer's Disease Positive TrendingData from 57 Per-Protocol PatientsSuggest NE3107 is Biologically Active and May Have Impact
BioVie announced positive topline efficacy data from its Phase 3 trial of NE3107 for mild to moderate Alzheimer's Disease, indicating potential cognitive improvements in treated patients. However, the trial faced significant challenges, including GCP violations at numerous sites, which led to the exclusion of a considerable number of patients, impacting the overall efficacy analysis. The company's management expressed commitment to rectifying issues while leveraging an adaptive trial design to address statistical significance in ongoing enrollment.
Read more →BIVIBioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer’s Disease
BioVie Inc. announced positive efficacy data from its Phase 3 trial of NE3107 in patients with mild to moderate Alzheimer's disease, suggesting cognitive benefits compared to placebo. Despite the promising findings, the primary efficacy endpoint did not achieve statistical significance due to significant Good Clinical Practice violations at some trial sites. The company has reported these violations to the FDA and is considering continuing patient enrollment to validate the treatment's efficacy. The trial indicates that NE3107 may offer advantages in cognitive functioning and biological age deceleration.
Read more →BIVIBioVie Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting 2023
BioVie Inc. announced positive clinical safety data from its Phase 2b trial of BIV201, a drug aimed at treating refractory ascites due to cirrhosis. The trial demonstrated that BIV201 combined with standard of care was well tolerated and showed no significant difference in adverse events compared to standard treatment alone. As a result of the findings, BioVie plans to initiate Phase 3 trials in Q2 2024, reaffirming its commitment to advancing BIV201 for patients facing a high mortality rate due to this condition.
Read more →BIVIBioVie to Participate in the Truist Securities BioPharma Symposium
BioVie Inc. will participate in the Truist Securities BioPharma Symposium on November 8-9, 2023, in New York. The company's management will present a panel on new modalities in Alzheimer's disease and conduct one-on-one investor meetings. BioVie is advancing its NE3107 drug candidate for Alzheimer's and Parkinson's diseases, alongside its FDA Fast Track designated BIV201 for liver disease. These developments may bolster investor interest and highlight the company's innovative drug therapies.
Read more →BIVIBioVie to Host Conference Call and Webcast Wednesday November 1, 2023 at 8:00 AM ET
BioVie Inc. announced a conference call and webcast on November 1, 2023, to discuss recent data on NE3017 presented at the 16th Clinical Trials on Alzheimer's Disease conference. The company's leadership will review findings that highlight the potential of their drug candidates NE3107 for Alzheimer's and Parkinson's diseases. Additionally, they will provide updates on their orphan drug candidate BIV201, which is under FDA Fast Track designation for liver disease treatment. The event aims to inform stakeholders about the company's advancements and clinical trials.
Read more →BIVIBioVie Announces Late-Breaking Abstract Presenting Clinical Safety Data from the Company’s Ascites Phase 2 Trial Accepted for Presentation at AASLD – The Liver Meeting 2023
BioVie Inc. announced that its clinical safety data from the Phase 2 trial of BIV201 will be presented at AASLD – The Liver Meeting 2023. The study evaluates the efficacy and safety of terlipressin in patients with refractory ascites due to cirrhosis. The presentation is scheduled for November 13, 2023, and aims to provide insights into the drug's safety and tolerability. BioVie is also advancing its programs in neurodegenerative disorders with promising data from trials of NE3107.
Read more →BIVIBioVie to Present Blinded Data on NE3107 in the Treatment of Mild to Moderate Alzheimer’s Disease at CTAD
BioVie Inc. announced that it will present blinded data from its Phase 3 clinical trial of NE3107 for mild to moderate Alzheimer’s Disease at the upcoming CTAD conference in Boston. The company has been monitoring blinded data throughout the trial to ensure patient safety and is preparing for database freeze and data unblinding. The topline data from this trial is expected to be announced in the November/December time frame, following the final treatment completion in September 2023.
Read more →BIVIFOR RELEASE OCTOBER 25, 2023 AT 12:20PM ET Blinded Data Presented at CTAD Suggest that NE3107 is Biologically Active and May Have Impact on Cognitive, Biomarker, and Imaging Endpoints Among Mild to Moderate Alzheimer's D
BioVie Inc. presented blinded data from its Phase 3 trial of NE3107 at the CTAD conference, indicating promising biological activity in mild to moderate Alzheimer's patients. The data suggested improvements in cognitive, biomarker, and imaging endpoints, alongside a significant reduction in amyloid plaque levels. The findings showed notable functional assessments and a favorable safety profile. BioVie plans to share unblinded results by late November or December 2023, hoping to validate NE3107's efficacy as a treatment option.
Read more →BIVIBioVie Announces Completion of Last Patient Treatment Visit in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer's Disease
BioVie Inc. has announced the completion of the last patient visit in its Phase 3 trial of NE3107 for mild to moderate Alzheimer's Disease. The company anticipates announcing topline data by November or December 2023, which will include cognitive and functional assessments. NE3107's potential to aid cognitive decline and its past favorable results in earlier trials provide a basis for optimism. However, the trial's success may hinge on subgroup analyses due to varying patient characteristics.
Read more →BIVIBioVie to Participate in the Cantor Fitzgerald Global Healthcare Conference
BioVie Inc. will participate in the Cantor Fitzgerald Global Healthcare Conference taking place in New York from September 26-28, 2023. The company is involved in developing therapies for neurological disorders, including Alzheimer's and Parkinson's diseases. Their drug candidate NE3107 has shown promising results in improving cognition and motor control in clinical trials. Additionally, BioVie is advancing the clinical testing of BIV201 for chronic liver cirrhosis, with FDA Fast Track status.
Read more →BIVIBioVie Presents Data Highlighting Baseline Characteristics of Study Population in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer’s Disease
BioVie Inc. presented preliminary baseline data from its Phase 3 trial of NE3107 for treating mild to moderate Alzheimer's Disease at the American Neurological Association meeting. The study population has significant underlying conditions that could affect cognitive function. Despite not revealing new data, the poster highlights important factors related to Alzheimer's risks. The trial aims for primary completion by the end of 2023, with hopes that NE3107 will demonstrate efficacy in improving cognitive metrics.
Read more →BIVIBioVie Hosting Virtual KOL Event on NE3107 in Alzheimer’s Disease Today, September 7, 2023
BioVie Inc. is organizing a virtual Key Opinion Leader event to present data and insights on its lead drug candidate, NE3107, aimed at treating mild to moderate Alzheimer's disease. The event is set for September 7, 2023, and will highlight NE3107's role in addressing neuroinflammation and insulin resistance, alongside presenting Phase 2 biomarker study results. The company anticipates topline Phase 3 data by the end of 2023, presenting an important step for its Alzheimer’s treatment efforts.
Read more →BIVIBioVie to Host Virtual KOL Event on NE3107 in Alzheimer’s Disease on September 7, 2023
BioVie Inc. has announced a virtual Key Opinion Leader (KOL) event to discuss its lead product, NE3107, on September 7, 2023. This event will provide insights into NE3107’s role in Alzheimer's treatment ahead of expected Phase 3 results later in 2023. Participants will hear from BioVie’s leadership and a prominent KOL about the drug’s mechanism and previous trial results, highlighting its potential benefit for Alzheimer’s patients. The company is optimistic that this therapy may significantly contribute to cognitive improvements.
Read more →BIVIBioVie Presents Data for NE3107 at 2023 International Congress of Parkinson’s Disease and Movement Disorders
BioVie Inc. presented promising preclinical data on NE3107 at the 2023 International Congress of Parkinson's Disease and Movement Disorders in Copenhagen. The studies indicated that NE3107 may improve motor function in patients with Parkinson's Disease, potentially acting as a first-line therapy. Pharmacokinetic analyses revealed that NE3107 does not adversely affect the efficacy of concomitant levodopa treatment. These findings exemplify the drug's role as a promising candidate for non-dopaminergic therapies in the treatment of neurodegenerative disorders.
Read more →BIVIBioVie Issues Letter to Shareholders
BioVie Inc. has demonstrated promising results from its Phase 2 exploratory trial of NE3107, a treatment for Alzheimer's Disease. The trial reported over 50% reductions in DNA methylation associated with cognitive and biomarker improvements. With no drug-related adverse events observed, the company's optimism grows ahead of the anticipated Phase 3 trial results. In addition, the data suggests that NE3107 could influence critical biological processes linked to cognition, indicating its potential efficacy in treating neurodegenerative conditions.
Read more →BIVIBioVie Presents Data Showing How NE3107 May Potentially Regulate DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease
BioVie Inc. presented data suggesting that treatment with NE3107 may significantly influence DNA methylation processes associated with cognitive improvements in dementia patients. The findings, presented at the Alzheimer's Association International Conference, highlight over 3,000 significant correlations between methylation reductions and various cognitive measures and biomarkers. The treatment appears to reduce inflammation and oxidative stress while potentially restoring gene expression, suggesting a novel mechanism for addressing cognitive disorders such as Alzheimer's and mild cognitive impairment.
Read more →BIVIBioVie to Present Data Showing How NE3107 Potentially Regulates DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease
BioVie Inc. announced the forthcoming presentation of data at the Alzheimer’s Association International Conference that details how its drug candidate NE3107 potentially regulates DNA methylation. This regulation is significantly correlated with observed cognitive improvements in patients treated with NE3107 for three months. The data could show the first statistically significant evidence of a pharmaceutical candidate's impact on reducing DNA methylation and its relationship to cognitive function and biomarkers related to Alzheimer's disease. The presentation is scheduled for July 16, 2023, in Amsterdam.
Read more →BIVIBioVie Presents Data Highlighting Role of Insulin Resistance and Neuroinflammation in the Development of Mild to Moderate in Alzheimer’s Disease
BioVie Inc. recently presented baseline data from its Phase 3 study of NE3107, an anti-inflammatory agent targeting Alzheimer's Disease, at the American Diabetes Association's Scientific Sessions. The study aims to assess NE3107's efficacy and safety in patients with mild to moderate AD. Significant findings highlighted the roles of insulin resistance and neuroinflammation, with several patient characteristics indicating metabolic dysregulation. While earlier trials showed promise, the current study still awaits outcome validation.
Read more →BIVIBioVie Set to Join the Russell 2000 and Russell 3000 Indexes
BioVie Inc. has announced its upcoming inclusion in the Russell 2000 and Russell 3000 indexes, effective June 26, 2023. This inclusion signifies a recognition of the company's growth and market capitalization. Russell indexes are utilized by a wide array of investment managers and institutional investors, which may enhance visibility and credibility for BioVie. The firm is known for developing innovative therapies for neurological and liver diseases and aims to leverage this recognition for potential future growth.
Read more →BIVIBioVie To Present of NE3017 in Alzheimer’s Disease Data at 83rd Scientific Sessions of the American Diabetes Association
BioVie Inc. announced it will present an abstract concerning its Phase 3 study of NE3107 for Alzheimer's disease at the 83rd Scientific Sessions of the American Diabetes Association. This study explores the connection between insulin resistance, neuroinflammation, and cognitive decline. NE3107 has previously shown potential in improving cognition in Alzheimer's as well as motor control in Parkinson's patients. The company is also working on BIV201 for liver disease, which is currently in a Phase 2b study.
Read more →BIVIBioVie Presents Rationale for Potentially Pivotal Trial of NE3107 in the Treatment of Parkinson’s Disease at 2023 International Association of Parkinsonism and Related Disorders World Congress
BioVie Inc. has presented promising data supporting a potentially pivotal clinical trial of NE3107 for Parkinson's disease at the 2023 IAPRD. The study showed that patients treated with NE3107 in combination with carbidopa/levodopa had greater improvements in motor symptoms compared to those on placebo. Importantly, the drug was well-tolerated, with no reported adverse safety signals, and demonstrated potential additional benefits in treating Alzheimer's disease. The company is encouraged to advance NE3107 into a Phase 3 trial based on these findings.
Read more →BIVIBioVie To Present Data from NE3107 Phase 2 Open-Label Trial at Society of Biological Psychiatry Annual Meeting
BioVie Inc. announced that data from its Phase 2 open-label trial evaluating NE3107 in degenerative dementias will be presented at the Society of Biological Psychiatry's Annual Meeting in San Diego. The presentation is scheduled for April 28, 2023, showcasing the effects of NE3107 on depression and cognitive decline. This follows previous positive results from NE3107 trials, including significant cognitive improvements in patients treated for Alzheimer's and Parkinson's diseases. Additionally, BioVie is developing BIV201, an orphan drug candidate for liver disease, currently in its Phase 2b study.
Read more →BIVIBioVie Announces Data Abstracts from NE3107 Phase 2 Trials Accepted for Presentation at AAN 2023
BioVie Inc. has announced that data abstracts from its Phase 2 trials of NE3107 in treating degenerative dementias and Parkinson's Disease will be presented at the 2023 American Academy of Neurology Annual Meeting. The presentations will showcase significant findings regarding the safety and efficacy of NE3107, particularly its ability to improve cognitive function and motor control in patients. Additionally, BIV201, an orphan drug candidate for liver disease, is undergoing a Phase 2b study with FDA Fast Track status, indicating ongoing development in critical therapeutic areas.
Read more →BIVIBioVie Announces Data from Phase 2 Parkinson’s Disease Trial Accepted for Presentation at AD/PD 2023
BioVie Inc. announced that data from its Phase 2 trial of NE3107 for Parkinson’s Disease will be presented at the upcoming AD/PD 2023 conference in Gothenburg, Sweden. The presentations will include both oral and poster formats, focusing on safety, tolerability, and efficacy. Recent topline data indicated significant improvements in motor control for patients receiving NE3107 in combination with levodopa. However, the company has noted potential risks associated with clinical trials that may impact their future plans and projections.
Read more →BIVIBioVie Announces Registration Details for "BioVie Day" Webinar
BioVie Inc. has announced registration details for its upcoming webinar, "BioVie Day," scheduled for March 23, 2023. The event will highlight the company's clinical programs in various neurological and liver diseases, including updates on their drug candidate NE3107. This candidate has shown promising Phase 2 trial results, particularly for Alzheimer's disease, and is also under evaluation for Parkinson's disease. The company's orphan drug candidate BIV201 is currently in a Phase 2b study with FDA Fast Track designation.
Read more →BIVIBioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial
BioVie Inc. has paused patient enrollment in its Phase 2b trial evaluating BIV201 for refractory ascites after observing promising data from the initial patient cohort. The treatment demonstrated a 34% decrease in ascites fluid, significantly outperforming standard care. The company is now engaging with the FDA to discuss moving directly to a pivotal Phase 3 trial, aiming to expedite bringing their therapy to market. Safety data was consistent, with no unexpected serious adverse events reported.
Read more →BIVIBioVie to Participate in the Oppenheimer 33rd Annual Healthcare Conference
BioVie Inc. announced its participation in the Oppenheimer 33rd Annual Healthcare Conference, scheduled for March 13-15, 2023. The company is focused on developing drug therapies for neurological disorders such as Alzheimer's and Parkinson's diseases, and advanced liver disease. Key highlights include a Phase 3 study of its drug candidate NE3107 for Alzheimer's, which previously showed promising results in Phase 2 trials. Additionally, the drug BIV201 for liver cirrhosis has achieved FDA Fast Track designation, emphasizing its potential importance in treatment.
Read more →BIVIBioVie Announces Additional Findings from Phase 2 Parkinson’s Disease Trial: More patients treated with NE3107 experienced morning “on state” with levodopa withheld overnight compared to those treated with placebo
BioVie Inc. announced additional preliminary findings from its Phase 2 trial of NE3107 in Parkinson's Disease, revealing that more patients showed a morning 'ON state' when levodopa was withheld overnight compared to those on placebo. This is significant as it indicates better control of motor symptoms, addressing a critical therapeutic need for patients. The trial has demonstrated encouraging efficacy, prompting the company to prepare for Phase 3 pivotal trials. Findings will be presented at the upcoming AD/PD 2023 Conference.
Read more →BIVIBioVie Announces Completion of Patient Enrollment in Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease
BioVie Inc. has announced the completion of patient enrollment for its Phase 3 NM101 clinical trial, which is assessing the efficacy of NE3107 in treating mild to moderate Alzheimer's disease. The enrollment target was revised to 400 patients, a decision made due to a faster enrollment pace than expected. Topline results from the trial are projected to be announced in October 2023, following the positive outcomes seen in a previous Phase 2 exploratory study. The trial aims to evaluate cognitive and functional improvements in Alzheimer's patients using NE3107.
Read more →BIVIBioVie Announces “BioVie Day” to be held March 23, 2023
BioVie Inc. has announced the scheduling of 'BioVie Day' on March 23, 2023, where it will present recent clinical trial data and discuss future plans. The event will focus on advancements in the company's programs for Alzheimer's Disease, Parkinson's Disease, and liver disease. BioVie will also reveal details about upcoming clinical trials and regulatory strategies. This gathering aims to enhance transparency with investors and analysts as the company gears up for scientific conferences and regulatory submissions.
Read more →BIVIBioVie Announces Additional Findings from Phase 2 Alzheimer’s Disease Trial: NE3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline in Dementia
CARSON CITY, Nev., Dec. 06, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced
Read more →BIVIBioVie Announces Positive Results for NE3107 in Parkinson's and Alzheimer's Phase 2 Trials NE3107-treated patients experienced greater motor control in Parkinson's trial Patients treated with the combination of NE3107 an
Announces Positive Results for NE3107 in Parkinson's and Alzheimer's patients experienced greater motor control in Parkinson's trial patients experienced improved cognition and biomarker levels in Alzheimer's trial City, NV, December 5, 2022 - BioVie Inc., (NASDAQ: BIVI) ("Bio
Read more →BIVIBioVie’s Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease Has Fully Enrolled the Targeted 316 Patients
CARSON CITY, Nev., Nov. 29, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced
Read more →BIVIBioVie to Present Data from Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer's Disease at CTAD Annual Meeting
CARSON CITY, Nev., Nov. 15, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced
Read more →BIVIBioVie to Present Data on Characterizing Hospitalization Burden of Ascites at AASLD Liver Meeting 2022
CARSON CITY, Nev., Oct. 24, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced
Read more →BIVIBioVie’s Phase 2 Trial Assessing NE3107's Pro-motoric Activity in Parkinson's Disease is Fully Enrolled
CARSON CITY, Nev., Oct. 19, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced
Read more →BIVIBioVie Issues Letter to Shareholders Positive preliminary data from investigator-sponsored Phase 2 Alzheimer's trial show high proportion of responders and level of cognitive improvements seen for NE3107 confirm NE3107's
Issues Letter to Shareholders City, NV, October 4, 2022 - BioVie Inc., (NASDAQ: BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today i
Read more →BIVIBioVie to Participate in Cantor Fitzgerald’s Neurology & Psychiatry Conference
RENO, Nev., Sept. 29, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced the
Read more →BIVIBioVie and Dr. Sheldon Jordan Jointly Announce Topline Results from an Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer's Disease BioVie Provides Updates on Other Cl
BioVie and Dr. Sheldon Jordan Jointly Announce Topline Results from an Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer's BioVie Provides Updates on Other Clinical Programs Carson City, NV, September 7, 2022 - BioVie In
Read more →BIVI▲ +10.7%on this news
BioVie Announces Patent Issuance Covering Ascites Treatment with BIV201
CARSON CITY, Nev., June 23, 2022 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced tha
Read more →BIVIDeveloping Transformative Therapies to Overcome Chronic Debilitating Diseases Corporate Presentation June 2022 2022 BioVie Inc. I Corporate presentation Forward - looking statements This document contains forward - looki
Developing Transformative Therapies to Overcome Chronic Debilitating Diseases Corporate Presentation June 2022 2022 BioVie Inc. I Corporate presentation Forward - looking statements This document contains forward - looking statements made pursuant to the safe harbor provisions o
Read more →BIVIBioVie to Participate at the B. Riley Securities’ Neuro & Ophthalmology Conference
CARSON CITY, Nev., April 25, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announc
Read more →BIVIBioVie Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report
CARSON CITY, Nev., March 10, 2022 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that an interview with Pre
Read more →BIVIBioVie to Participate at the Oppenheimer Virtual Annual Healthcare Conference
RENO, Nev., March 09, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced the
Read more →BIVIBioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinson’s Disease
RENO, Nev., Jan. 20, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders today announced the tre
Read more →BIVIBioVie to Participate at the LifeSci Partners 11th Annual Corporate Access Event
RENO, Nev., Dec. 28, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced the p
Read more →BIVIBioVie Announces Partnership with the American Liver Foundation
RENO, Nev., Dec. 09, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that
Read more →BIVIBioVie Secures Up to a $25.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P. Reno, NV
BioVie Secures Up to a $25.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P. Reno, NV, December 1, 2021 - BioVie Inc., (NASDAQ: BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative dr
Read more →BIVIBioVie Hosting Key Opinion Leader Webinar on Complications of Advanced Liver Cirrhosis and BIV201 Phase 2b Clinical Trial Update
RENO, Nev., Nov. 04, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that
Read more →BIVIBioVie Announces the Appointment of a New Chief Medical Officer
RENO, Nev., Nov. 01, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurodegenerative disease - announced today the appointment of Joseph M. Palumbo, MD, LFAPA, MACPsych, as
Read more →BIVIBioVie Announces FDA Authorization to Initiate Phase 2 Trials Assessing NE3107’s Pro-motoric Activity in Parkinson’s Disease
SANTA MONICA, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announ
Read more →BIVIBioVie Hosting Key Opinion Leader Webinar on Neuroinflammation and Insulin Resistance and New Treatment Approaches for Alzheimer’s Disease
SANTA MONICA, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announ
Read more →BIVIBioVie to Present at Cantor Virtual Global Healthcare Conference
SANTA MONICA, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today annou
Read more →BIVIBioVie to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Virtual Summit
SANTA MONICA, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurodegenerative disorders and advanced liver disease, today announced the particip
Read more →BIVIBioVie Inc. Announces Closing of Public Offering of Common Stock
SANTA MONICA, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders, liver disease and certain cancers, toda
Read more →BIVIBioVie Inc. Announces Pricing of Public Offering of Common Stock
BioVie Inc. Announces Pricing of Public Offering of Common Stock SANTA MONICA, Calif., August 8, 2021 (GLOBE NEWSWIRE) - BioVie Inc., (NASDAQ: BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug therapies for the treatment of neurological and
Read more →BIVIBioVie Inc. Announces Proposed Public Offering of Common Stock
SANTA MONICA, Calif., Aug. 06, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders, liver disease and certain cancers, toda
Read more →BIVIBioVie Announces First Patient Enrolled in Phase 3 Study of NE3107 in Alzheimer s Disease
Announces First Patient Enrolled in Phase 3 Study of NE3107 in Alzheimer s Disease MONICA, Calif., August 5, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ( BioVie or Company ), a clinical-stage company developing innovative drug candidates for the treatment of neurologi
Read more →BIVIBioVie Presents Data Supporting use of NE3107 in the Treatment of Alzheimer’s Disease at 2021 Alzheimer’s Association International Conference
SANTA MONICA, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease, neurodegenerative disease and certain cancers, announced today that a poster by Christopher L Reading, PhD, BioVi
Read more →BIVIBioVie to Present Rationale for use of NE3107 for the Treatment of Alzheimer’s Disease at 2021 Alzheimer’s Association International Conference
SANTA MONICA, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease, neurodegenerative disease and certain cancers, announced today that Poster 55458 entitled “Rationale for an Anti-
Read more →BIVIBioVie Added to Russell Microcap Index
SANTA MONICA, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neuro-degenerative disorders and certain cancers, toda
Read more →BIVIBioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
SANTA MONICA, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neurodegenerative disorders and certain cancers, today announced an interview with Terren Pei
Read more →BIVIBioVie Announces First Patient Enrolled in BIV201 Phase 2b Clinical Trial for Ascites
SANTA MONICA, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neurodegenerative disorders and certain cancers, today
Read more →BIVIBioVie Receives FDA Guidance for Phase 3 Clinical Trial of BIV201 in HRS-AKI
SANTA MONICA, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neurodegenerative disorders and certain cancers, today
Read more →BIVIBioVie Announces Closing of Acquisition of BioPharma Assets from Privately Held NeurMedix Company Expects to Commence Enrollment in Pivotal Phase 3 Alzheimer's Trial in Mid-2021
Announces Closing of Acquisition of BioPharma Assets from Privately Held NeurMedix Company Expects to Commence Enrollment in Pivotal Phase 3 Alzheimer's Trial in Mid-2021 SANTA MONICA, Calif., June 11, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company")
Read more →BIVIBioVie Hosting Research & Development Day
SANTA MONICA, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neuro-degenerative disorders and certain cancers, today
Read more →BIVIBioVie Announces Amended Terms for Asset Acquisition from Privately Held NeurMedix
BioVie Announces Amended Terms for Asset Acquisition from Privately Held NeurMedix SANTA MONICA, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for chronic debilitating
Read more →BIVIBioVie to Present at 2021 B. Riley Securities’ Neuroscience Conference
SANTA MONICA, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and, pending closing of the announced transaction with NeurMedix, neurolog
Read more →BIVIBioVie Acquires Biopharma Assets from Privately Held NeurMedix Includes Pivotal Phase 3 Alzheimer s Asset NE3107 Cuong V. Do Named CEO of The New BioVie Conference Call Scheduled for
Acquires Biopharma Assets from Privately Held NeurMedix Pivotal Phase 3 Alzheimer s Asset NE3107 Cuong V. Do Named CEO of The New BioVie Conference Call Scheduled for April 27, 2021 at MONICA, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ( BioVie or C
Read more →BIVIBioVie to Present at 31st Annual Oppenheimer Healthcare Conference
SANTA MONICA, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today announced the participation of its management team in the 31st Annual Oppenheimer He
Read more →BIVIBioVie Commences Patient Screening in Phase 2 Clinical Trial
SANTA MONICA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today announced the start of patient screening in the Company’s Phase 2 Trial of BIV201 (c
Read more →BIVIBioVie Interview to Air on Bloomberg TV in the US on the RedChip Money Report
SANTA MONICA, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today announced an interview with Terren Peizer, Chairman and Chief Executive Officer, will
Read more →BIVIBioVie Interview to Air on Bloomberg International on the RedChip Money Report
SANTA MONICA, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today announced an interview with Terren Peizer, Chairman and Chief Executive Officer, will
Read more →BIVIBioVie to Participate in B. Riley Securities Liver Disease Therapeutics Day on October 29, 2020
SANTA MONICA, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today announced that it will participate in the B. Riley Securities’ Liver Disease Therapeut
Read more →BIVIBioVie Announces Closing of Public Offering of Common Stock -- Includes Full Exercise of Underwriters' Overallotment Option -- SANTA MONICA, CA / GLOBE NEWSWIRE /
BioVie Announces Closing of Public Offering of Common Stock -- Includes Full Exercise of Underwriters' Overallotment Option -- SANTA MONICA, CA / GLOBE NEWSWIRE / September 23, 2020 / BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing inn
Read more →BIVIBioVie Advances the BIV201 Clinical Program and Prefilled Syringe
Novel BIV201 Formulation Shows Significant Improvements Over Industry Terlipressin Prefilled Syringe May Significantly Extend Market Protection Beyond Orphan Drug Exclusivity SANTA MONICA, Calif., June 11, 2020 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB: BIVI) (“BioVie” or “Company
Read more →BIVIBioVie Manufactures Novel Terlipressin Prefilled Syringe
SANTA MONICA, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB: BIVID) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, announced today that its first batch of BIV201 prefilled syringes containing a patent-pendi
Read more →BIVIBioVie Achieves Primary Objectives in Phase 2a Clinical Trial of BIV201 in Refractory Ascites
LOS ANGELES, April 30, 2019 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB: BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, today announced top-line results for its Phase 2a clinical trial of BIV201 (continuous infusion terl
Read more →BIVIBioVie to Present at ThinkEquity Conference in NYC on May 2nd
LOS ANGELES, April 24, 2019 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB: BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, announced that Mr. Terren Peizer, the Company’s Chairman and CEO, is scheduled to participate in the
Read more →BIVIBioVie Completes Patient Enrollment for its Phase 2a Clinical Trial of BIV201 in Refractory Ascites
LOS ANGELES, Feb. 06, 2019 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for liver disease, announced today that it has completed enrollment in a Phase 2a open-label clinical study of BIV20
Read more →BIVIBioVie's New Drug Candidate BIV201 Receives FDA Orphan Drug Designation for the Treatment of Hepatorenal Syndrome (HRS) BioVie Inc. (OTCQB: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovativ
BioVie's New Drug Candidate BIV201 Receives FDA Orphan Drug Designation for the Treatment of Hepatorenal Syndrome (HRS) BioVie Inc. (OTCQB: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for liver disease, announced today that
Read more →BIVIBioVie Inc. (OTCQB:BIVI) Attains Milestone
BEVERLY, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB:BIVI), a clinical-stage company focused on the development and commercialization of innovative drug therapies for liver disease, announced today that it has achieved 50% enrollment of the patients in its open-l
Read more →BIVIBioVie to Present at The MicroCap Conference in New York on April 9th
BEVERLY, Mass., March 22, 2018 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB:BIVI), a clinical-stage company focused on the development and commercialization of innovative drug therapies for liver disease, announced today that it will participate in The MicroCap Conference taking place
Read more →BIVIBioVie Responds to Japan Patent Office and Comments on Recent Stock Price Decline
BEVERLY, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB:BIVI), a clinical-stage company focused on the development and commercialization of innovative drug therapies for liver disease, announced today that it submitted a response to questions raised by the Japanese
Read more →BIVIBioVie Receives FDA Clearance of IND Application for Phase 2a Clinical Trial in Refractory Ascites Patients BioVie's Core Patent Covering BIV201 as Treatment for Ascites Allowed by US Patent Office Conditions Satisfied t
Receives FDA Clearance of IND Application for 2a Clinical Trial in Refractory Ascites Patients BioVie's Core Patent Covering for Ascites Allowed by US Conditions Satisfied to Commence Funding Under the Aspire Capital $12 Million Common Stock Purchase MA - (Marketwired - Ap
Read more →BIVIBioVie Enters Into A $12 Million Common Stock Purchase Agreement With Aspire Capital Fund -- BIV201 Clinical Trial May Begin This Spring -- BEVERLY, MA - (
BioVie Enters Into A $12 Million Common Purchase Agreement With Aspire Capital -- BIV201 Clinical Trial May Begin BEVERLY, MA - (January 5, 2017) - BioVie Inc. (OTCBB: BIVI), a development-stage company focused on the discovery, development, and commercialization of innovativ
Read more →BIVILAT PHARMA LLC AUDITED FINANCIAL STATEMENTS DECEMBER 31, 2014, and DECEMBER 31, 2015 1095 Evergreen Circle, Ste 200, The Woodlands, Texas 77380 | (832) 482-4611 | Fax: (832) 442-5077
AUDITED FINANCIAL STATEMENTS 1095 Evergreen Circle, Ste 200, The Woodlands, Texas 77380 | (832) 482-4611 | Fax: (832) 442-5077 To the Partners LAT Pharma LLC Street, Unit B Chicago, IL 60605 We have audited the accompanying comparative statement of assets, liabilities and e
Read more →Competitive Position
How BIVI ranks across every disease it competes inCompetitive Position is a premium feature
See how BIVI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial